J&J's Caplyta clears a big hurdle for bipolar mania

Johnson & Johnson announced that its drug Caplyta successfully met the primary endpoint of a late-stage clinical trial for bipolar mania — a significant step toward expanding the drug's approved uses. Patients receiving a once-daily 42 mg dose showed meaningful symptom reduction compared to placebo, with improvements emerging as early as three days into treatment and sustained throughout the three-week study.

The trial also hit a key secondary endpoint measuring overall illness severity, strengthening the case for a potential label expansion. Caplyta is already approved in the U.S. for depressive episodes in bipolar I and II disorder and for schizophrenia. J&J acquired the drug through its $14.6 billion purchase of Intra-Cellular Therapies earlier this year to grow its neuroscience portfolio.

By the Numbers

• ~46% of Caplyta-treated patients achieved a clinical response vs. ~21% on placebo
• 37 million people worldwide are estimated to be affected by bipolar disorder
• Improvements observed as early as 3 days after starting treatment

Why it matters: Bipolar mania remains a challenging condition to treat, and a new approved option could meaningfully expand care choices for the millions living with bipolar I disorder globally.